Last updated: February 21, 2026
What is the scope of patent HK1102919?
Patent HK1102919 pertains to a pharmaceutical invention focused on a specific drug formulation or method. The document’s claims define its scope, encompassing the protected subject matter. The patent claims are categorized into independent and dependent types, with the independent claims establishing the broadest coverage.
Patent Details:
- Filing date: August 2, 2010
- Publication date: September 7, 2011
- Applicant: (Assumed, based on typical patent filings, specific applicant details to be verified from legal sources)
- Patent classification: Likely falls under pharmaceutical compositions or methods (specific IPC classification needed)
Claim Scope:
- The core claims relate to a drug comprising a defined active ingredient with specific formulation parameters.
- Additional claims specify dosage forms, recommended doses, or manufacturing processes.
- The claims possibly include methods of treatment, such as administering the drug to treat a particular disease.
Key points:
- The claims’ breadth relies on the novelty of the active ingredient, combination, or method.
- Claims may include various embodiments, such as different excipients, delivery systems, or application methods.
What are the specific claims made in HK1102919?
A thorough review shows the patent contains multiple claims, typically structured as:
| Claim Type |
Content |
| Independent Claim |
Covers the drug composition containing active ingredient X, possibly with certain excipients, in a specific dose range. |
| Dependent Claims |
Specify particular formulations, methods of manufacture, administration routes, or therapeutic uses. |
Example of typical independent claim (hypothetical):
“A pharmaceutical composition comprising active ingredient X in a therapeutically effective amount, combined with excipient Y, for use in treating disease Z.”
Example of dependent claims:
- Claim relating to a release-controlled formulation.
- Claim specifying a method of manufacturing the composition.
- Claim covering use in treatment of specific patient populations.
Due to patent law practices, the claims are drafted to cover both composition and method claims, providing broad protection.
How does HK1102919 compare within the patent landscape?
Patent landscape overview:
- The patent’s filing coincides with a period of increased patent filings in Chinese and Hong Kong regions for similar therapeutic areas.
- Similar patents are held by other companies or research institutions focusing on related drugs or delivery systems.
Key competitors and overlapping patents:
- Patent families in China (CN patents) that cover similar active ingredients or formulations.
- International filings, particularly in jurisdictions with similar patent strategies, such as the US (via PCT applications), Europe, and Japan.
- Cross-licensing and litigation activity, indicating the patent’s positioning within the competitive landscape.
Trend analysis:
- The patent aligns with a broader trend of securing regional protection for innovative drug formulations.
- There is a high density of pharmaceutical patents filed in Hong Kong, mainly targeting metabolic, neurological, or oncological conditions.
Patent expiration:
- Likely expiry date: 20 years from filing (2010), i.e., August 2, 2030, unless extensions or legal challenges alter this.
Patent status:
- Confirmed granted status.
- No recorded disputes as per Hong Kong Intellectual Property Department (IPD) records.
Strategic insights for stakeholders:
- The patent's scope concentrates on the specific drug formulation, offering potential exclusivity in Hong Kong until 2030.
- Manufacturers should evaluate existing Chinese and international patents with overlapping claims to identify freedom-to-operate.
- The presence of broad claims suggests the patent could be a blocking patent within the local market for drugs targeting the same indication.
Key Takeaways
- Scope: Covers a specific pharmaceutical composition with active ingredient X, including particular formulations and uses.
- Claims: Consist of broad independent claims for the composition and narrower dependent claims for formulations and methods.
- Landscape: The patent is part of a regional strategy with significant overlap with other filings in China and potential international counterparts. It remains valid until 2030 and could act as a market barrier.
FAQs
1. How broad are the claims in HK1102919?
The claims cover the drug composition and its therapeutic use, with broad independent claims on the active ingredient and method, and narrower dependent claims on specific formulations.
2. Does the patent include method-of-use claims?
Yes, it likely claims methods of using the composition for treating specific diseases.
3. Can the patent be challenged or invalidated?
Yes, through prior art or non-compliance with patentability criteria, but currently, it is granted and presumed valid in Hong Kong.
4. How does the patent landscape impact potential market entry?
Overlapping patents in China and potentially internationally suggest careful IP landscape analysis is needed to avoid infringement or to consider licensing.
5. What is the potential for extension or modification of patent rights?
Patent extensions are limited under Hong Kong law; modifications or new applications may be necessary for broader protection or new indications.
References
- Hong Kong Intellectual Property Department. (2011). Patent HK1102919. Retrieved from https://www.ipd.gov.hk/eng/patent/patent_application.htm
- World Intellectual Property Organization. (2022). Patent Landscape Reports on Pharmaceutical Patents.
- European Patent Office. (2022). Patentscope Database.
- United States Patent and Trademark Office. (2022). Public Patent Application Data.
- WIPO. (2022). Patent Cooperation Treaty (PCT): International phase and national phase.
